HomeLegal DirectoryFDA AI/ML SaMD Action Plan

In effect Moderate protection

FDA AI/ML SaMD Action Plan — Software as a Medical Device

United States · FDA AI/ML SaMD Action Plan (Jan. 12, 2021)

FDA's 5-part roadmap for regulating AI/ML-based Software as a Medical Device, including a proposed Predetermined Change Control Plan framework that lets developers update models without full FDA re-review.

Technical detail

FDA AI/ML SaMD Action Plan (Jan. 12, 2021): articulates 5 actions — (1) tailored regulatory framework with PCCP, (2) GMLP, (3) patient-centered transparency, (4) regulatory science methods for bias and robustness, (5) real-world performance monitoring. Foundation for FDA's AI/ML SaMD reviews and the 2024 Transparency Guiding Principles.

Who is protected: Patients receiving care that involves AI/ML medical devices

Who must comply: Manufacturers of AI/ML SaMD

Key facts

JurisdictionUnited States
LevelFederal
StatusIn effect
Protection strengthModerate protection
Effective date2021-01-12
Enacted2021-01-12
CitationFDA AI/ML SaMD Action Plan (Jan. 12, 2021)
Enforced byFDA / CDRH
Private right of actionNo — agency enforcement only
PenaltiesFDCA enforcement: warning letters, recalls, civil penalties
Topicshealthcare AI · automated decision-making
Last verified2026-06-16
Official sourceFDA AI/ML SaMD Action Plan (PDF) ↗

More AI rules in United States

Related healthcare AI rules elsewhere

See something wrong or out of date? Submit a correction — every entry must carry a verifiable official source.